fun reading
Our minds are not physically connected to our bodies.
travel at the speed of thought
>you will be left with infinite anguish when you realize that either you have to serve, or regain freedom by force
https://nypost.com/2021/09/28/anthony-bourdain-friends-reveal-all-sex-drugs-tanning/
Other recollections delight in Bourdain’s quick wit. Celebrity chef Nigella Lawson talks of shooting the cooking-competition show “The Taste” in Los Angeles with Bourdain. He would stay at the infamous Chateau Marmont and often order room service, despite the fact that the food was mediocre and the trays weren’t taken away quickly. When she complained, he told her: “Nigella, you’re getting the Chateau all wrong. Obviously they can’t do room service cleanup, but if you kill someone by accident, they will remove the body, no questions asked.”
Nice bum, where you from?
https://nypost.com/2021/09/29/its-wonderful-to-watch-dems-rip-each-other-apart/
Get the popcorn! It’s wonderful to watch Dems rip each other apart
“Seems to me this would be a good time to send, no strings attached, a check for $200 million to Iran.”
In the above video, taken at April 3, 1987 campaign stop in Claremont, New Hampshire, Biden can be seen sparring with a voter who questioned his academic credentials. Biden responded, "I think I have a much higher I.Q. than you do I suspect. I went to law school on a full academic scholarship – the only one in my class to have a full academic scholarship." Biden went on to claim that he graduated in the top half of his law school. Problem is, none of that is true.
That's one way to greet a hostage.
Theranos
https://en.wikipedia.org/wiki/Andrew_Ross_Sorkin
He is a member of the Council on Foreign Relations.
Sorkin has a coloboma in his left eye that sometimes makes it appear as if he has two different colored eyes.
>He is a member of the Council on Foreign Relations.
https://web.archive.org/web/20151012005313/http://everything-pr.com/40-under-40-list/41903/
The UJA-Federation of New York just released their 40-under-40 list of the top movers and shakers in the New York community today. Participants were chosen for their “drive, determination, achievement, character, and ability to lead the community.”
Award recipients included many known to the communications community, including PR agency CEO Matthew Hiltzik, of Hiltzik Strategies who represents Justin Bieber, Alex Baldwin, Harvey Weinstein and others. Media awardees included Andrew Ross Sorkin, author and journalist with The New York Times and DealBook, Peter Rosenberg of New York’s Hot 97, and Samantha Yanks of Niche Media which produces luxury magazines.
>Alex Baldwin, Harvey Weinstein
"What an idiot that Harvey Weinstein is," Baldwin's Trump said. "He could have gotten away with it all that if he'd gotten himself elected as president."
>A firm spiritual foundation is essential.
https://en.wikipedia.org/wiki/Manoir_Richelieu
In 1985, businessperson Raymond Malenfant bought the hotel from the Province of Quebec for $555,555.55 (equivalent to $1,208,113 in 2020). Malenfant refused to recognize the union for the then 300-350 employees at the hotel, claiming he had bought the building, not the collective agreement. Two of Malenfant's cars were torched. Workers broke into the hotel and ransacked the facilities resulting in 71 arrests. One person died of suffocation while in police custody. After an extended conflict all the workers lost their jobs and the union was crushed. Malenfant, worth hundreds of millions in the 1980s, was bankrupt by the early 1990s because of the dispute. The dispute is considered one of the nastiest in Quebec labor history.
The Casino de Charlevoix adjoins the hotel and can be accessed via an underground passage.
>The Casino de Charlevoix adjoins the hotel and can be accessed via an underground passage.
https://en.wikipedia.org/wiki/Casino_de_Charlevoix
https://www.bbc.com/news/magazine-21859771
1913: When Hitler, Trotsky, Tito, Freud and Stalin all lived in the same place
https://web.archive.org/web/20170429201408/https://aspe.hhs.gov/cdc-%E2%80%94-influenza-deaths-request-correction-rfc
"US data on influenza deaths are false and misleading. The Centers for Disease Control and Prevention (CDC) acknowledges a difference between flu death and flu associated death yet uses the terms interchangeably. Additionally, there are significant statistical incompatibilities between official estimates and national vital statistics data. Compounding these problems is a marketing of fear—a CDC communications strategy in which medical experts "predict dire outcomes" during flu seasons."
APPLY TO COVID-19 DATA REPORTS.
https://www.gatesfoundation.org/Ideas/Media-Center/Press-Releases/2010/12/Global-Health-Leaders-Launch-Decade-of-Vaccines-Collaboration
Global Health Leaders Launch Decade of Vaccines Collaboration | Bill & Melinda Gates Foundation
NEW YORK – The World Health Organization (WHO), UNICEF, the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation have announced a collaboration to increase coordination across the international vaccine community and create a Global Vaccine Action Plan. This plan will build on the successes of current work to achieve key milestones in the discovery, development and delivery of lifesaving vaccines to the most vulnerable populations in the poorest countries over the next decade.
The collaboration follows the January 2010 call by Bill and Melinda Gates for the next ten years to be the Decade of Vaccines. The Global Vaccine Action Plan will enable greater coordination across all stakeholder groups – national governments, multilateral organizations, civil society, the private sector and philanthropic organizations – and will identify critical policy, resource, and other gaps that must be addressed to realize the life-saving potential of vaccines.
The structure of the Decade of Vaccines Collaboration includes a Leadership Council to provide oversight for the planning effort, a Steering Committee that holds the primary responsibility for developing the action plan, an International Advisory Committee to assist the Leadership Council in evaluating the action plan, and a Secretariat for administrative support.
Prof. Pedro Alonso, Director for the Institute for Global Health of Barcelona and Dr. Christopher Elias, President and CEO of PATH, have been appointed co-chairs of the Steering Committee and the Secretariat.
“Vaccines are miracles,” said Prof. Alonso, “For just a few dollars per child, vaccines prevent disease and disability for a lifetime. We must make sure that people understand that vaccines are one of the best investments in health.”
The Decade of Vaccines Collaboration expects to complete its work by mid-2012. At that time, all vaccine stakeholder groups will be responsible for implementing the action plan.
“We look forward to working with the global vaccine community to extend the benefits made possible by existing vaccines and new vaccines in development,” said Dr. Elias, “Together we can ensure that all children have a shot at a healthy life.”
https://gcgh.grandchallenges.org/about/scientific-board
Bill and Melinda Gates foundation Global Grand Challenges
Anthony S. Fauci, M.D., Member, Scientific Board
Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
United States
https://www.bloomberg.com/news/articles/2020-02-05/china-is-trying-to-patent-gilead-s-experimental-coronavirus-drug
https://outline.com/b3mKq9
China Is Trying to Patent Gilead’s Experimental Coronavirus Drug
February 05, 2020
China has applied for a new patent on an experimental Gilead Sciences Inc. drug that its scientists believe might fight the coronavirus.
It has applied for a patent for the use of the drug, know as remdesivir, to treat the novel coronavirus. The move is a sign that China views Gilead’s therapy as one of the most promising candidates to fight the outbreak that has now claimed almost 500 lives. A patent battle may affect Gilead’s control over the drug in China.
While Gilead’s experimental drug isn’t licensed or approved anywhere in the world, it is being rushed into human trials in China on coronavirus patients after showing early signs of being highly effective.
The patent application was made on Jan. 21, according to a statement posted on the website of the virology institute in Wuhan, the central Chinese city at the epicenter of the epidemic. Scientists there have found Gilead’s remdesivir, and chloroquine, an 80-year-old malaria drug, “highly effective” in laboratory studies at thwarting the novel coronavirus, they said Tuesday in a paper in the journal Cell Research. The two drugs’ efficacies on humans required further clinical tests, the institute said in the statement.
China is capable of manufacturing chloroquine and now wants access to remdesivir. It is not clear if or when China’s intellectual property authorities will approve the institute’s application.
Gilead’s experimental drug is at present entering clinical trials in China on patients with the novel coronavirus. The company is shipping enough doses to treat 500 patients and is ramping up supply in case the clinical trials work.
Remdesivir is being tested in two trials in China in patients with moderate and severe symptoms of the novel pathogen, said Merdad Parsey, Gilead’s chief medical officer.
The Wuhan institute said in its statement that it made the patent application out of national interest, and won’t exercise its patent rights if foreign pharmaceutical firms work together with China to curb the contagion.
>The Wuhan institute said in its statement
https://web.archive.org/web/20200204175556/http://www.whiov.ac.cn/kyjz_105338/202002/t20200204_5497136.html
Chinese scholars have made important progress in anti-2019 new coronavirus drug screening
Recently, the Wuhan Institute of Virology/Biosafety Science Research Center of the Chinese Academy of Sciences and the National Emergency Prevention and Control Drug Engineering Technology Research Center of the Academy of Military Medicine of the Academy of Military Sciences conducted a joint study, and achieved results in drug screening for the suppression of the 2019 novel coronavirus (2019-nCoV) Important progress. Related research results were published under the title "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro" ("Remdesivir and chloroquine phosphate can effectively inhibit the new coronavirus (2019-nCoV) in vitro") In Cell Research ("Cell Research"), an internationally renowned academic journal with independent intellectual property rights in China.
The study showed that on Vero E6 cells, Remdesivir (GS-5734) has a half effective concentration of 2019-nCoV EC50=0.77 uM (micromole per liter), the selection index SI is greater than 129; Chloroquine phosphate (Chloroquine) ) EC50=1.13 uM, SI is greater than 88, indicating that the above two drugs can effectively inhibit 2019-nCoV infection at the cellular level, and their effects in humans have yet to be clinically verified.
Remdesivir (GS-5734) is a nucleoside analogue, currently in the Congo (DRC) phase II and III clinical studies for the treatment of Ebola hemorrhagic fever. Chloroquine phosphate (Chloroquine) has been used for the treatment of malaria since the 1940s and later for the treatment of rheumatoid arthritis. The preliminary results of the above two drugs effectively inhibiting the 2019 novel coronavirus infection at the cellular level have previously been reported to relevant national, provincial and municipal departments in various forms. In order to serve the prevention and control of the epidemic, the two parties jointly declared: Among the above-mentioned drugs with anti-2019 new coronavirus effects, we will not apply for related patents for the drug chloroquine phosphate that has been marketed in China and can be fully supplied independently, in order to encourage related The enthusiasm of enterprises to participate in the prevention and control of the epidemic; for the drug Remdesivir, which is not yet on the market in China and has intellectual property barriers, we applied for a Chinese invention patent on January 21 from the perspective of protecting national interests in accordance with international practices ( Anti-2019 novel coronavirus use), and will enter the world's major countries through the PCT (Patent Cooperation Agreement) route. If relevant foreign companies intend to contribute to the prevention and control of the epidemic in our country, we both agree that if the country needs it, we will not require the implementation of the rights claimed by the patent for the time being. We hope to cooperate with foreign pharmaceutical companies to contribute to the prevention and control of the epidemic. force.
Researcher Wang Manli of Wuhan Institute of Virology, Associate Researcher Cao Ruiyuan of National Emergency Prevention and Control Drug Engineering Research Center of Military Medical Research Institute, Associate Researcher Zhang Leipi, Associate Researcher Yang Xinglou of Wuhan Institute of Virology are the co-first authors of the paper, researcher Xiao Gengfu of Wuhan Institute of Virology, Researcher Zhong Wu of the National Emergency Prevention and Control Drug Engineering Technology Research Center of the Academy of Military Medical Sciences and researcher Hu Zhihong of Wuhan Institute of Virology are the co-corresponding authors, and Liu Jia, Xu Mingyue, Shi Zhengli and others are the co-authors. Participants in the project are Wang Xi, Wu Yan, Shang Weijuan, Zhang Huanyu, Li Yufeng, Hu Hengrui, Jiang Xiaming, Sun Yuan from Wuhan Institute of Virology. This work has been strongly supported by the National Virus Resource Bank and Wuhan National Biosafety Laboratory, as well as the "Major New Drug Creation" National Science and Technology Major Project (2018ZX09711003), the National Natural Science Foundation of China Innovation Group Project (31621061) and Hubei Province 2019 New Type Pneumonia Emergency Technology Funding for research projects.
Link to the paper: https://www.nature.com/articles/s41422-020-0282-0
>https://www.nature.com/articles/s41422-020-0282-0
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro. Since these compounds have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease.